Core Insights - Catheter Precision, Inc. has successfully completed the first LockeT procedures in France, marking a significant step in the adoption of its cardiac electrophysiology technologies in Europe [1][2] - The procedures were conducted at CHU Rennes, which is also a commercial partner for the company's VIVO product line [2] - The LockeT device is designed to improve procedural efficiency and patient outcomes following cardiac ablation procedures, indicating a strong market need in Europe [3] Product Information - LockeT is a suture retention device aimed at assisting in wound closure after percutaneous venous punctures, classified as a Class 1 device with FDA registration and CE Mark approval [4] - VIVO (View Into Ventricular Onset) is a non-invasive 3D imaging system that helps identify the origin of ventricular arrhythmias before procedures, thus streamlining workflow and reducing procedure time; it has also received FDA marketing clearance and CE Mark [5] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, emphasizing collaboration with physicians and continuous product advancement [6]
Catheter Precision Announces First Procedures in France as LockeT Expansion Continues